Other probiotics

Bacillus coagulans (SC208)

Bacillus coagulans is a gram-positive, spore-forming, microaerophilic, lactic-acid producing bacillus. It was originally isolated and described in 1932 by Horowitz and Wlassowa and named Lactobacillus sporogenes (L. sporogenes). In 1957, the organism was reclassified in Bergey’s Manual of Determinative Bacteriology based on its biochemical properties, and the current correct nomenclature is Bacillus coagulans (B. coagulans). Bacillus coagulans is unique in that it shows characteristics of both Bacillaceae and Lactobacillaceae. It shares certain characteristics such as production of lactic acid with genus Lactobacillus; however it forms spores like other Bacillus members and in contrast to Lactobacillus members.

B. coagulans is a probiotic, well known for its clinical efficacy in several human conditions. B. coagulans has been granted Qualified Presumption of Safety (QPS) status since 2008 by the European Food Safety Authority and also has GRAS status issued by USFDA.

Bacillus coagulans (SC208™)

The benefits of Bacillus coagulans (SC208)

  • B. coagulans is a remarkably resilient probiotic that is able to withstand extreme conditions (like high temperatures, processing, stomach acids and bile) and is room temperature-stable for up to 3 years.
  • The spores of B. coagulans pass on to the duodenum intact where the spores germinate and transform into viable vegetative cells, producing lactic acid and bacteriocins etc. which render the intestinal environment non-conducive for the growth of harmful pathogenic bacteria.
  • B. coagulans produces only L-Lactic acid hence easily used by the body unlike the racemic mixture of Lactic acid that cause acidosis. This isomer has a greater effect on immune stimulation and gut defense and safer than the other forms of lactic acid produced by conventional probiotics such as Lactobacillus species.
  • B. coagulans possesses significant β-galactosidase (lactase) activity in vitro and may also have lactic acid dehydrogenase activity, thereby enhancing the digestibility of lactose in those who are lactose intolerant.
  • It increases protein digestion and uptake in the upper gastrointestinal (GI) tract and consequently also reduced the amount of protein that would be delivered to the colon, which could then be fermented into toxic metabolites by the gut microbiota.
  • B. coagulans was shown to be among the most promising probiotics for prevention and treatment of antibiotic-associated diarrhea, irritable bowel syndrome (IBS), functional bowel disorders, flatulence and vaginitis.
Bacillus licheniformis (SL307)

Bacillus licheniformis is a ubiquitous organism consumed by humans for millions of years. Bacillus licheniformis is a gram-positive, spore-forming bacterium and is a close relative of Bacillus subtilis. Bacillus licheniformis is a Generally Recognized as Safe (GRAS) organism in the United States by the Food and Drug Administration (FDA) standard for safety and toxicity of bacterial strains and has Qualified Presumption of Safety (QPS) designation in the European Union (EU).

Bacillus licheniformis (SL307™)

The benefits of Bacillus licheniformis (SL307)

  • B. licheniformis spores are able to withstand the presence of bile salts and low gastric pH and thus reaches the gut intact.
  • It produces a number of important compounds, most importantly the antibiotic Bacitracin which is effective against many pathogenic bacteria. Bacitracin is a thermostable antibiotic that is resistant to enzymatic degradation, making it extremely effective in the gut.
  • Bacillus licheniformis produces several digestive enzymes such as protease, α-amylase, β-mannanase and several pectinolytic enzymes.
  • Protease enzyme is vital for digesting and assimilating proteins in the body.
  • Bacillus licheniformis has also shown to be a potent animal probiotic especially in the pig & poultry sectors and in aquaculture.
Bacillus clausii (SC109)

Bacillus clausii is a probiotic widely used in Italy since the1960s for viral diarrhea in children and for antibiotic associated diarrhea.
B. clausii is an aerobic, spore-forming bacterium that is able to survive transit through the acidic environment of the stomach and colonize the intestine even in the presence of antibiotics. It is said to have been identified by name in 1995 by German bacteriologist Dieter Claus.

Bacillus clausii (SC109™)

The benefits of Bacillus clausii (SC109)

  • B. clausii possesses antimicrobial and immunomodulatory activities.
  • B. clausii is extremely stable to acidic conditions, hence the entire dose of ingested bacteria reach the small intestine intact.
  • Both Bacillus clausii (B. clausii) spores and cells can adhere to the bowel wall and colonize the mucosa.
  • B. clausii can inhibit the growth of pathogens in the gastrointestinal tract via three distinct mechanisms: colonization of free ecological niches, which are no longer available for the growth of other microorganisms; competition for epithelial cell adhesion; production of antibiotics and/or enzymes secreted into the intestinal environment, especially peptide antibiotics, which are mainly active on pathogenic bacteria.
  • Bacillus clausii is a probiotic capable of modulating the immune response. Specifically, it has been demonstrated that B. clausii stimulates Th1 and Treg immunity, promoting IL-12, IFN-γ, IL-10, and transforming growth factor-beta (TGF-β) synthesis, and down-regulates Th2 response, inhibiting IL-4 production.
  • It helps replenish microbial flora during antibiotic treatment.
  • Thus, B. clausii is an effective probiotic of choice in the treatment of diarrhea and prevention of antibiotic associated diarrhea. It has the added advantage of being a spore forming probiotic making it a very resilient, stable probiotic which can be stored at room temperature.